Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc.

ANTH - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.62K
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Anthera Pharmaceuticals, Inc.Anthera Pharmaceuticals, Inc.0--181%--

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2,618.00
Enterprise Value$-8,083,382.00
Earnings per Share$-1.65
Beta-5.81
Outstanding Shares22,166,869

Return

Return on Equity-180.63%ROE
Return on Assets-111.95%
Return on Invested Capital-377.49%

Valuation & Multiples

P/E Ratio0P/E Ratio
PEG0PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.35
Enterprise Value to Net Income0
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Anthera Pharmaceuticals, Inc.

21 employees
CEO: Mr. Paul F. Truex M.B.A.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replac...

Anthera Pharmaceuticals Insider Information FAQ

In the latest 13F quarter on Stockcircle, 2 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.